Dyadic International, Inc.

Good evening and welcome to Dyadic International Q3 2024 conference call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief question and answer session. As a reminder, this conference call is being recorded today, November 12, 2024. I would now like to turn the call over to Ms. Ping Rawson, Dyadic's Chief Financial Officer. Please go ahead.

Thank you. Good evening and welcome everyone to Dyadic International's Q3 2024 conference call. I hope you have had an opportunity to review Dyadic's press releases announcing financial results for the quarter ended September 30, 2024. You may access our release and form 10Q and their investor session of the company's website at dyadic.com. On today's call, our president and CEO, Mark Emelfar, and our chief operating officer, Joe Hazleton, will give a review of our third quarter 2024 business and corporate highlights and provide a commentary on the strategic direction of the business. I will follow with a review of our financial results in more detail. We'll then hold a brief question and answer session. At this time, I would like to inform you that certain commentary made in this conference call may be considered forward-looking statements, which involve risks and uncertainties and other factors that could cause dietics actual results, performance, scientific or otherwise, or achievements to be materially different from those expressed or implied by these forward-looking statements. Dietics expressly disclaims any duty to provide updates to its forward-looking statements, whether because of new information, future events, or otherwise. Participants are directed to the risk factors set forth in DIATIC's report filed with the SEC. It is now my pleasure to pass the call to our CEO, Mark Emelbart. Mark?

Thank you, Ping. Welcome, everyone, and thank you for joining DIATIC's Q3 2024 conference call. We are excited to discuss how our business strategy centered on near-term licensing and product candidates has strategically positioned IATIC to swiftly take advantage of current and upcoming opportunities. Our dedicated focus on achieving multiple revenue streams and significant milestones through commercialization of products, technology licensing, fully funded collaborations, advancing our internal and external pipelines are yielding tangible results. These third quarter achievements strongly highlight Dyadic's commitment to harnessing the full potential of our proprietary Dapabase and C1 microbial protein production platforms. These innovative technologies are the foundation for driving both immediate and sustainable revenue, particularly through the commercialization of alternative proteins targeted for high-value applications such as recombinant human albumin, transferrin, and DNase I. At the same time, we're laying the groundwork for substantial mid- and long-term growth in human and animal health markets. This dual-track strategy enables Dyadic to capitalize on near-term milestones, generating license revenue and achieving significant progress in product development by applying our DAPRBIS platform to develop and produce enzymes and proteins to help address complex and evolving needs in health, nutrition, and wellness, such as dairy proteins, including alpha-lactalbumin and others. Simultaneously, our biopharmaceutical pipeline, powered by our CMWIN platform, holds significant opportunity. For example, we are collaborating with Verovax to develop potential vaccines for infectious diseases such as bird flu and mpox. Additionally, our collaborations with two of the top 10 pharmaceutical companies and the leading biotech company have yielded progress in producing several commercially relevant proteins such as an antibody targeting digestive health and multiple antigens in large infectious disease markets such as HPV, RSV, and HIV. We are advancing collaborations with leading nonprofit organizations and governmental agencies to further accelerate the adoption of our C1 protein production platform due to the many advantages the C1 cell platform offers, such as speed of development and manufacturing, high productivity, cost efficiency, and flexibility of use in diverse applications of vaccines and treatments for infectious and other diseases. They can be produced in greater quantities more affordably, more patients for more patients in developed and developing countries. As we continue advancing our efforts across all segments, we remain deeply committed to delivering sustained value to our investors and partners. Dyadic is poised not only to meet the challenges today, but to shape the health, wellness, and nutrition solutions of tomorrow. Positioning ourselves as leaders in the global protein production of enzymes, Alternative Proteins in Biopharmaceutical Sectors. I will now turn the call over to our Chief Operating Officer, Joe Hazelton, to provide an update on our business results for the third quarter. Joe?